Anne Lowell, BS

Medical Content Manager

Anne Lowell is a Medical Content Manager and Clinical Health Coach. She holds a Bachelor of Science in Health & Fitness from the University of Michigan and brings over a decade of experience as a Registered Yoga Teacher, Licensed Massage Therapist, Board Certified Health & Wellness Coach, and ACSM Certified Exercise Physiologist.

GLP-1 medications work. That part is no longer a question.

In clinical trials, semaglutide (Wegovy) produces an average weight loss of 13–15% at the standard 2.4 mg dose and nearly 19% at the newer, higher 7.2 mg dose (Wegovy HD). Tirzepatide (Zepbound) pushes that to 20% or more. These are among the most effective pharmaceutical treatments for obesity ever developed, and in 2026, they’re being prescribed at an unprecedented scale.

But “effective” is a more complicated word than it looks. The same body of research that proves GLP-1s produce significant weight loss also shows that most patients stop treatment within a year, that weight regain after discontinuation is rapid and substantial, and that side effects are the leading cause of dropout.

So the real question isn’t whether GLP-1s work. It’s whether they work durably, and what it takes to make that happen.

Here’s what the latest research says.

GLP-1 Weight Loss Results: What the Clinical Data Actually Shows

GLP-1 receptor agonists are highly effective for weight loss. Across clinical trials, the evidence is consistent and substantial.

Semaglutide (Wegovy) produces an average of 13.7% body weight loss at 68–72 weeks. In the STEP trial program, 86% of participants lost at least 5% of their body weight, and roughly half lost 15% or more.

In March 2026, the FDA approved a higher dose, Wegovy HD (semaglutide 7.2 mg). In the 72-week STEP UP trial of 1,407 adults with obesity (BMI of 30 or higher, without diabetes), the 7.2 mg dose produced 18.7% average weight loss. About 91% of participants on 7.2 mg lost at least 5% of their body weight.

Tirzepatide (Zepbound), a dual GIP/GLP-1 receptor agonist, produces even greater results. In the SURMOUNT trial program, participants on the highest dose (15 mg) lost an average of 22.5% of their body weight at 72 weeks, with more than 70% achieving at least 15% weight loss.

To put this in context: these results approach what was historically only achievable through bariatric surgery. For many patients, GLP-1 therapy represents the first pharmaceutical option that produces clinically meaningful, sustained weight reduction.

How Do Tirzepatide and Semaglutide Compare?

The SURMOUNT-5 trial, published in the New England Journal of Medicine in 2025, provided the first head-to-head comparison of tirzepatide versus semaglutide in adults with obesity (without diabetes).

The results were clear: tirzepatide produced 20.2% mean weight loss at 72 weeks, compared to 13.7% with semaglutide 2.4 mg, a 6.5 percentage point advantage. Participants on tirzepatide were twice as likely to achieve 25% or more weight loss. Real-world data from over 18,000 patients confirmed these findings, with tirzepatide users losing 15.3% versus 8.3% for semaglutide at 12 months. Note that the 7.2 mg dose of semaglutide hasn’t been compared head-to-head with tirzepatide. 

Both medications had similar gastrointestinal side effect profiles, with most adverse events being mild to moderate and occurring primarily during dose escalation. Notably, treatment discontinuation due to side effects was actually lower with tirzepatide (2.7%) than semaglutide (5.6%).

However, the optimal medication for any individual depends on medical history, side-effect tolerance, access, cost, and sustainability. Higher efficacy in a trial doesn’t automatically mean a better outcome for every patient. What matters is matching the right medication to the right person, and surrounding it with the right support.

Oral GLP-1 Pills: A New Option With New Tradeoffs

For most of the GLP-1 era, effective obesity treatment meant a weekly injection. That changed in the span of a few months. Between December 2025 and April 2026, the FDA approved two oral GLP-1 pills for chronic weight management, giving patients who prefer to avoid needles two distinct options—each with its own efficacy profile and its own daily-use requirements.

Oral Wegovy (semaglutide 25mg) 

In December 2025, the FDA approved oral semaglutide (Wegovy tablets) for chronic weight management—the first GLP-1 pill approved for obesity.

In the OASIS 4 trial, oral semaglutide 25 mg produced 13.6% mean weight loss at 64 weeks versus 2.2% with placebo. More than 75% of participants achieved at least 5% weight loss, and 30% achieved 20% or more. These results are broadly comparable to injectable semaglutide 2.4 mg.

The tradeoff is in the daily routine. Oral Wegovy must be taken once daily on an empty stomach first thing in the morning with water, followed by a 30-minute wait before any food, drink, or other medications. That fasting requirement, combined with daily (rather than weekly) dosing, creates adherence challenges and a higher risk of missed doses.

Foundayo (orforglipron)

In April 2026, the FDA approved orforglipron (Foundayo). Unlike semaglutide, which is a peptide that requires strict fasting to be absorbed, orforglipron is a small molecule that can be taken once daily with or without food and without water restrictions. For patients who struggle with the empty-stomach protocol, this is the most meaningful practical difference between the two pills.

Efficacy sits somewhat below oral Wegovy in cross-trial terms. In the 72-week ATTAIN-1 trial of adults with obesity but without diabetes, the highest dose produced an 11.2% mean weight reduction versus 2.1% with placebo; more than one-third of patients lost at least 15% and nearly one-fifth lost at least 20%. In ATTAIN-2, which enrolled adults with obesity and type 2 diabetes, the highest dose produced roughly 10% weight loss versus about 2.5% with placebo, alongside meaningful HbA1c reductions. 

While orforglipron may offer greater convenience for some patients, it is associated with four times as many adverse-event–related discontinuations. Orforglipron also lacks cardiovascular outcomes data, meaning that—unlike semaglutide—its long-term cardiometabolic benefit remains presumed rather than proven.

The Discontinuation Problem: Most Patients Stop Within a Year

Here’s where the effectiveness picture gets complicated.

A 2025 study of 125,474 adults found that most patients discontinue GLP-1 therapy within the first year. Among those without type 2 diabetes, the population most likely using GLP-1s specifically for weight management, 64.8% stopped treatment within 12 months. Only 36.3% of those who stopped reinitiated therapy within a year.

These aren’t marginal numbers. They represent the majority of patients walking away from a therapy that was working.

What Drives GLP-1 Discontinuation?

The research identifies four primary drivers:

Gastrointestinal side effects remain the leading cause. Moderate-to-severe GI adverse events, such as nausea, vomiting, diarrhea, and constipation, increase discontinuation risk by 19-38%. These side effects are most common during dose escalation and typically subside, but without proactive management, many patients stop before they improve.

Inadequate early weight loss creates a perception gap. Each 1% reduction in body weight was associated with a 3% lower risk of stopping therapy. Patients who don’t see results quickly enough may lose motivation, even though optimal results often take 6-12 months.

Cost and access barriers disproportionately affect adherence. Among diabetes patients, higher income was associated with 28% lower discontinuation rates. For weight management patients, out-of-pocket costs remain a significant hurdle, especially when employer coverage is limited or absent.

Lack of perceived medical necessity affects patients without diabetes more than those with it. Without a clear “chronic disease” framing, some patients view GLP-1 therapy as optional, something they can stop once they’ve lost enough weight. The research tells a different story.

Weight Regain After Stopping GLP-1s: What the Evidence Shows

Weight regain after GLP-1 discontinuation is one of the most well-documented findings in obesity research, and one of the most important for anyone evaluating these therapies.

Multiple meta-analyses published in 2025 confirm a consistent pattern: weight regain is rapid and substantial, even when patients continue lifestyle interventions after stopping medication.

The numbers are stark. Patients who discontinue semaglutide or tirzepatide regain an average of 9.69 kg (approximately 21 lbs). Up to two-thirds of lost weight is regained within one year. Weight regain occurs at approximately 0.55% of original body weight per month, meaning most patients return to their baseline weight within about 1.7 years of stopping.

A post-hoc analysis of the SURMOUNT-4 trial revealed that the consequences extend beyond the scale. Patients who regained 75% or more of their lost weight experienced significant increases in blood pressure, waist circumference, and BMI, eroding the cardiometabolic benefits that made the treatment worthwhile in the first place.

What This Means

The weight regain data doesn’t mean GLP-1s failed. It means obesity is a chronic condition that requires ongoing treatment, the same way hypertension or diabetes does. Programs designed as short-term interventions (“lose the weight, then stop the medication”) are working against the biology.

The WHO’s first-ever global guidelines on GLP-1 therapies for obesity, published in 2025, reinforce this framing. The guidelines explicitly recognize obesity as a chronic, relapsing disease requiring long-term management, and recommend sustained GLP-1 therapy combined with intensive behavioral support.

Managing GLP-1 Side Effects: Evidence-Based Strategies

Since side effects are the leading driver of discontinuation, effective side-effect management is directly tied to treatment success.

Gastrointestinal symptoms are the most common challenge: nausea affects 33-44% of patients, diarrhea 23-31%, and vomiting 11-25%. These typically peak within 48 hours of initiation or dose escalation and are usually mild to moderate.

The newer 7.2 mg dose of semaglutide (Wegovy HD) adds a few considerations. In the STEP UP trial, nausea, vomiting, and constipation were somewhat more common than at the standard dose. 

Evidence-based management strategies include slower titration schedules (monthly dose escalation, or even slower for sensitive patients), dietary modifications (smaller meals, reduced fat intake, avoiding alcohol), short-term pharmacologic support (ondansetron for severe nausea, H2 blockers for dyspepsia), and dose optimization, or finding a sustainable effective dose rather than always pushing to the maximum.

In clinical trials, 6-10% of patients permanently discontinued due to adverse events. But real-world discontinuation rates are substantially higher, 53% within one year, suggesting that the structured support available in clinical trials (regular check-ins, titration guidance, proactive side-effect management) makes a meaningful difference in persistence.

The implication is clear: the support infrastructure around the medication matters as much as the medication itself. Programs that combine clinical oversight, nutritional guidance, behavioral coaching, and proactive monitoring can reduce avoidable discontinuation and improve long-term outcomes.

Beyond Weight Loss: Cardiovascular and Metabolic Benefits

GLP-1 therapies deliver benefits that extend well beyond the number on the scale, and these broader effects may ultimately drive more long-term value than weight loss alone.

The evidence base is growing. Semaglutide 2.4 mg reduced major adverse cardiovascular events in people with obesity and established cardiovascular disease in the landmark SELECT trial. Blood pressure reductions of 7-10 mm Hg systolic and LDL cholesterol reductions of approximately 9% have been observed across trials. Tirzepatide has been approved for moderate-to-severe obstructive sleep apnea in adults with obesity. Emerging data suggest potential benefits for chronic kidney disease.

A post-hoc analysis of SURMOUNT-5 found that tirzepatide was associated with significantly greater 10-year cardiovascular disease risk reduction compared to semaglutide (2.4% absolute reduction vs. 1.4%).

For self-insured employers evaluating GLP-1 coverage, these cardiometabolic benefits may represent the most compelling cost argument. Avoiding cardiovascular events, reducing hypertension management costs, and fewer obesity-related comorbidity claims can drive savings that compound over time.

What Makes GLP-1 Programs Actually Work

The research paints a consistent picture: GLP-1 medications are highly effective, but their real-world impact depends almost entirely on the care model surrounding them.

Programs that treat GLP-1s as a standalone pharmaceutical intervention, i.e., prescribing the medication, stepping back, and hoping for the best, face predictable challenges: high discontinuation rates, unmanaged side effects, and weight regain when treatment eventually stops.

Programs that embed GLP-1s into comprehensive, long-term care with clinical oversight, behavioral coaching, nutritional support, side-effect management, and comorbidity treatment see better persistence, better outcomes, and more sustainable value.

Based on the latest evidence, effective GLP-1 programs share five characteristics:

They treat obesity as a chronic condition. Budget and coverage decisions account for sustained treatment, not time-limited interventions. The weight regain data make clear that short-term approaches produce short-term results.

They manage side effects proactively. Structured titration protocols, proactive monitoring, and access to clinical support reduce the 50-65% discontinuation rate that undermines program ROI.

They provide behavioral infrastructure. The WHO guidelines, multiple clinical advisory boards, and the discontinuation research all point to the same conclusion: GLP-1s work best when combined with intensive behavioral therapy, nutritional support, and lifestyle interventions.

They address comorbidities. Weight rarely exists in isolation. 84% of people with obesity have at least one comorbid condition such as chronic pain, sleep dysfunction, depression, or metabolic disease. Programs that treat only weight while ignoring the conditions that make weight loss difficult are solving half the problem.

They match medication to the individual. With tirzepatide and semaglutide showing different efficacy profiles, and oral formulations expanding the options, medication selection should be personalized based on clinical profile, not defaulted to the lowest-cost option.

Frequently Asked Questions

How effective are GLP-1 medications for weight loss?

GLP-1 medications are among the most effective pharmaceutical treatments for obesity. In clinical trials, semaglutide (Wegovy) produces average weight loss of 13–15% of body weight, while tirzepatide (Zepbound) produces 20% or more. More than 85% of patients achieve at least 5% weight loss, which is the threshold for clinically meaningful health improvement.

Is tirzepatide (Zepbound) more effective than semaglutide (Wegovy)?

Yes, compared with the standard 2.4 mg dose of semaglutide. The SURMOUNT-5 trial showed tirzepatide produced 20.2% weight loss versus 13.7% for semaglutide 2.4 mg at 72 weeks, and tirzepatide users were twice as likely to lose 25% or more of their body weight. A higher 7.2 mg dose of semaglutide (Wegovy HD), approved in March 2026, produced 18.7% weight loss in the STEP UP trial, but it has not been compared head-to-head with tirzepatide. The best medication for any individual depends on their medical history, side-effect tolerance, and access.

What happens when you stop taking a GLP-1 for weight loss?

Weight regain after GLP-1 discontinuation is rapid and well-documented. Patients who stop semaglutide or tirzepatide regain an average of 21 lbs, with up to two-thirds of lost weight returning within one year. Cardiometabolic benefits, including blood pressure and cholesterol improvements, also deteriorate with weight regain.

Why do most people stop GLP-1 medications within a year?

Approximately 50-65% of patients discontinue GLP-1 therapy within 12 months. The primary drivers are gastrointestinal side effects (which increase discontinuation risk by 19-38%), cost barriers, inadequate early weight loss, and a perception that treatment is optional rather than ongoing. Structured support programs significantly reduce avoidable discontinuation.

Does oral Wegovy work as well as the injection?

Clinical data suggest oral semaglutide (Wegovy tablets) is broadly comparable to the injectable version. In the OASIS 4 trial, oral semaglutide 25 mg produced 13.6% weight loss at 64 weeks. The pill eliminates needle aversion but requires daily dosing and strict fasting, which may affect real-world adherence differently than weekly injections.

Are GLP-1s safe long-term?

GLP-1 medications have been used for over 15 years in diabetes treatment, with an established safety profile. The most common side effects are gastrointestinal (nausea, diarrhea, vomiting), typically mild-to-moderate and most pronounced during dose escalation. The WHO’s 2025 global guidelines support long-term use for obesity, while acknowledging that ongoing research into extended safety is warranted.

1. World Health Organization. Guideline on the Use and Indications of Glucagon-Like Peptide-1 Therapies for the Treatment of Obesity in Adults. JAMA. 2025.

2. Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. N Engl J Med. 2025;393(1):26-36.

3. Wharton S, Freitas P, Hjelmesæth J, et al. Once-weekly Semaglutide 7.2 mg in Adults with Obesity (STEP UP): A Randomised, Controlled, Phase 3b Trial. Lancet Diabetes Endocrinol. 2025;13(11):949-963.

4. Rodriguez PJ, Goodwin Cartwright BM, Gratzl S, et al. Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity. JAMA Intern Med. 2024;184(9):1056-1064.

5. Rodriguez PJ, Zhang V, Gratzl S, et al. Discontinuation and Reinitiation of Dual-Labeled GLP-1 Receptor Agonists Among US Adults With Overweight or Obesity. JAMA Network Open. 2025;8(1):e2457349.

6. Kushner RF, Almandoz JP, Rubino DM. Managing Adverse Effects of Incretin-Based Medications for Obesity. JAMA. 2025.

7. Zhou L, Wei A, Pan C, et al. Effects of Glucagon-Like Peptide-1 Receptor Agonists After Treatment Withdrawal: A Systematic Review and Meta-Analysis. J Gen Intern Med. 2025.

8. Berg S, Stickle H, Rose SJ, Nemec EC. Discontinuing Glucagon-Like Peptide-1 Receptor Agonists and Body Habitus: A Systematic Review and Meta-Analysis. Obes Rev. 2025;26(8):e13929.

9. Horn DB, Linetzky B, Davies MJ, et al. Cardiometabolic Parameter Change by Weight Regain on Tirzepatide Withdrawal in Adults With Obesity. JAMA Intern Med. 2025.

10. FDA Approval: Oral Semaglutide for Chronic Weight Management. December 2025.

11. Wharton S, Aronne LJ, Stefanski A, et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. N Engl J Med. 2025.

12. Overgaard RV, Birkhan O, Rathor N, et al. Efficacy, Safety and PK of Once-Daily Oral Semaglutide 25 mg for Obesity With and Without Type 2 Diabetes in Comparison With Subcutaneous Semaglutide 2.4 mg: A Model-Informed Drug Development Approach. Diabetes Obes Metab. 2026.

13. Horn DB, Ryan DH, Kis SG, et al. Orforglipron for the Treatment of Obesity in People With Type 2 Diabetes (ATTAIN-2). Lancet. 2026.

14. Schweitzer K. What to Know About the New Semaglutide Pill for Obesity. JAMA. 2026.

15. Rosenstock J, Yabe D, Cox D, et al. Efficacy and Safety of Once-Daily Oral Orforglipron Compared With Oral Semaglutide in Adults With Type 2 Diabetes (ACHIEVE-3): A Multinational, Multicentre, Non-Inferiority, Open-Label, Randomised, Phase 3 Trial. Lancet. 2026.

16. Michalak W, Bøg M, Bendixen T, et al. Oral Semaglutide 25 mg Versus Orforglipron 36 mg in Obesity: A Population-Adjusted Indirect Treatment Comparison. Diabetes Obes Metab. 2026.

17. Nauck MA, Tuttle KR, Tschöp MH, Blüher M. Glucagon-Like Receptor Agonists and Next-Generation Incretin-Based Medications: Metabolic, Cardiovascular, and Renal Benefits. Lancet. 2026.

18. American Diabetes Association. Standards of Care in Diabetes — 2026. Diabetes Care. 2026;49(Supplement_1):S166-S182.